# A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes

Study · id `cardio:ct-nct07112872` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07112872](<https://clinicaltrials.gov/study/NCT07112872>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07112872

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 330 participants.

## Technical summary

Registry record NCT07112872. Randomized; double masking; primary purpose treatment. Start 2025-08-19 (actual); primary completion 2028-02-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 330 participants (planned count; ClinicalTrials.gov record NCT07112872, source copy `cardio:ctgov-nct07112872-2026-11-12`, retrieved 2026-11-18)
- Started: 2025-08-19 (actual) (ClinicalTrials.gov record NCT07112872, source copy `cardio:ctgov-nct07112872-2026-11-12`, retrieved 2026-11-18)
- Primary completion: 2028-02-05 (anticipated) (ClinicalTrials.gov record NCT07112872, source copy `cardio:ctgov-nct07112872-2026-11-12`, retrieved 2026-11-18)
- Completion: 2028-02-05 (anticipated) (ClinicalTrials.gov record NCT07112872, source copy `cardio:ctgov-nct07112872-2026-11-12`, retrieved 2026-11-18)
- Countries: United States; Hungary; Poland; Spain (ClinicalTrials.gov record NCT07112872, source copy `cardio:ctgov-nct07112872-2026-11-12`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07112872-2026-11-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Tifeglipron
- Intervention (Drug): Semaglutide
- Intervention (Drug): Placebo
- Lead sponsor: Hoffmann-La Roche
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Hoffmann-La Roche (`cardio:org-hoffmann-la-roche`)

## Provenance

Content hash: d04ccc808e36e8ff7c4ed89f790077632b8df95ef2ce80bf17ef0e9dc8323219
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
